Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 5/20 | 0.48 |
| ▸ | ABAT | P80404 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GRM8 | O00222 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.32 |
| ▸ | OAT | P04181 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Icofungipen SCHEMBL7791325 | 1.00 | GABRR1 (0.48) | GABRR1ABATGRM4CYP2C19TDP1 | |
| Icofungipen SCHEMBL3950387 | 1.00 | GABRR1 (0.48) | GABRR1ABATGRM4CYP2C19TDP1 | |
| Icofungipen SCHEMBL3950389 | 1.00 | GABRR1 (0.48) | GABRR1ABATGRM4CYP2C19TDP1 | |
| Icofungipen SCHEMBL6268839 | 1.00 | GABRR1 (0.48) | GABRR1ABATGRM4CYP2C19TDP1 | |
| Icofungipen SCHEMBL6268842 | 1.00 | GABRR1 (0.48) | GABRR1ABATGRM4CYP2C19TDP1 | |
| SCHEMBL1030623 | 0.83 | GABRR1 (0.39) | GABRR1GRM4CYP2C19TDP1MEN1 | |
| SCHEMBL1030281 | 0.83 | GABRR1 (0.39) | GABRR1GRM4CYP2C19TDP1MEN1 | |
| SCHEMBL8413192 | 0.83 | GABRR1 (0.39) | GABRR1GRM4CYP2C19TDP1MEN1 | |
| SCHEMBL1030622 | 0.83 | GABRR1 (0.39) | GABRR1GRM4CYP2C19TDP1MEN1 | |
| SCHEMBL8261790 | 0.77 | GABRR1 (0.37) | GABRR1GRM4CYP2C19TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118548269-A | AHMA type hydraulic operating mechanism travel test method | 中国长江电力股份有限公司 | 2024-08-27 | — | — | CN | claimed |
| CN-118528007-A | Maintenance method for AHMA type energy storage piston of operating mechanism | 中国长江电力股份有限公司 | 2024-08-23 | — | — | CN | claimed |
| CN-118514037-A | AHMA type disassembly and overhaul method for hydraulic operating mechanism | 中国长江电力股份有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-118007273-A | Method for preparing high ultraviolet light absorption capacity composite fiber membrane based on electrostatic spinning | 浙江理工大学 | 2024-05-10 | — | — | CN | claimed |
| CN-116012687-A | Image interaction fusion method for identifying tread defects of wheel set | 湖南工业大学 | 2023-04-25 | — | — | CN | claimed |
| US-11311625-B2 | Peptide-based multiple-drug delivery vehicle | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 2022-04-26 | — | — | US | claimed |
| US-12606830-B2 | Protected antibody-drug and aptamer-drug conjugates | KOSAK KENNETH MICHAEL (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4306515-B1 | 3-HYDROXYADIPIC ACID 3,6-LACTONE COMPOSITION | TORAY INDUSTRIES (JP) | 2026-02-04 | — | — | EP | disclosed |
| US-12467016-B1 | Air purification candle | Glow Guardian, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2025-10-07 | — | — | US | disclosed |
| US-20250302953-A1 | METHODS OF TREATING PATIENTS EXHIBITING A PRIOR FAILED THERAPY WITH HYPOIMMUNOGENIC CELLS | SANA BIOTECHNOLOGY, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| CN-119886035-A | Large-scale design-oriented high-efficiency area and line length optimization macro layout method | 广东工业大学 | 2025-04-25 | — | — | CN | disclosed |
| EP-0805145-B1 | Efficient and highly enantioselective process for the preparation of enantiomerically pure cylopentane-beta-amino acids | BAYER AG (DE) | 2001-10-31 | — | — | EP | disclosed |
| EP-0754678-B1 | Improvement of physiological tolerance of pharmaceutical active beta-amino acids | BAYER AG (DE) | 2001-01-03 | — | — | EP | disclosed |
| EP-1043332-A1 | Dipeptides comprising cyclopentan-beta-amino acids | Bayer Aktiengesellschaft (DE) | 2000-10-11 | — | — | EP | disclosed |
| US-5935988-A | MIXTURES OF 2-AMINO-4-METHYLENECYCLOPENTANECARBOXYLIC ACID WITH ISOLEUCINE, ALANINE OR PROLINE | BAYER AKTIENGESELLSCHAFT (DE) | 1999-08-10 | — | — | US | disclosed |
| US-5877343-A | Efficient and highly enantioselective process for the preparation of enantiomerically pure cyclopentane-β-amino acids | BAYER AKTIENGESELLSCHAFT (DE) | 1999-03-02 | — | — | US | disclosed |
| EP-0805145-A1 | Efficient and highly enantioselective process for the preparation of enantiomerically pure cylopentane-beta-amino acids | BAYER AG (DE) | 1997-11-05 | — | — | EP | disclosed |
| EP-0754678-A2 | Improvement of physiological tolerance of pharmaceutical active beta-amino acids | BAYER AG (DE) | 1997-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606830-B2 | Protected antibody-drug and aptamer-drug conjugates | PABPC1, PABPC4, ABCG2 | GABRR1 4066/4885ABAT 1028/4885GRM4 1436/4885 |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | ABCB11, ABCB1, GHRHR | GABRR1 2273/4885ABAT 1214/4885GRM4 3357/4885 |
| US-11311625-B2 | Peptide-based multiple-drug delivery vehicle | VIP, NGLY1, IAPP | GABRR1 1004/4885ABAT 2927/4885GRM4 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.